LadRx

LadRx EBITDA per Employee

The EBITDA per Employee of LadRx (LADX) as of Oct 17, 2026 is -1.81 M USD. In the previous year, EBITDA per Employee was -1.91 M USD — a change of -4.94% (higher).

EBITDA per Employee

-1.81 MUSD

YoY

-4.94%

Last updated:

EBITDA per Employee of LadRx is 2024 -1.81 M USD. EBITDA per Employee of LadRx was 2023 -1.91 M USD. It decreases by -4.94% higher compared to the previous year.

The LadRx EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-4.12 M USD
Jan 1, 2019
-3.92 M USD
Jan 1, 2020
-3.40 M USD
Jan 1, 2021
-2.98 M USD
Jan 1, 2022
-2.27 M USD
Jan 1, 2023
-1.91 M USD
Jan 1, 2024
-1.81 M USD
The LadRx EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-1.81 MUSD-4.94%
-1.91 MUSD-16.14%
-2.27 MUSD-23.82%
-2.98 MUSD-12.27%
-3.40 MUSD-13.28%
-3.92 MUSD-4.93%
-4.12 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LadRx Stock analysis

What does LadRx do? LadRx Corp, with ticker LADX and ISIN US2328287071, is a biotechnology company headquartered in Los Angeles, United States. The company has 2 employees and went public on November 10, 1986. Its website is http://www.cytrx.com/. LadRx Corp operates within the Health Care sector, specifically in the Biotechnology industry. The company's activities include the discovery, research, and clinical development of anti-cancer drug candidates. It focuses on aldoxorubicin, a modified version of doxorubicin, for clinical development. The company is involved in Phase III trials for aldoxorubicin as a treatment for soft tissue sarcoma in patients whose tumors have progressed after chemotherapy. Additionally, LadRx Corp is conducting Phase IIb trials for aldoxorubicin in small cell lung cancer, Phase II trials for HIV-related Kaposi's sarcoma, and Phase II trials for late-stage glioblastoma. The company also has Phase Ib trials combining aldoxorubicin with ifosfamide for soft tissue sarcoma and with gemcitabine for metastatic solid tumors. LadRx Corp is developing DK049, an anti-cancer drug conjugate utilizing its LADR technology, in pre-clinical stages. The company's website and public filings provide further details on its operations and clinical trials. LadRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LadRx stock

EBITDA per Employee of LadRx is -1.81 M USD in 2024.

EBITDA per Employee of LadRx changed from -1.91 M USD to -1.81 M USD, representing a -4.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee LadRx since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's LadRx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — LadRx

All Key Metrics — LadRx